UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017198
Receipt number R000019956
Scientific Title Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes
Date of disclosure of the study information 2015/04/27
Last modified on 2018/09/11 15:51:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes

Acronym

Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes

Scientific Title

Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes

Scientific Title:Acronym

Evaluation for Efficacy of Rosuvastatin on Carotid Intima Media Thickness and Characteristics of Atherosclerosis in Hyperlipidemic Patients with Type 2 Diabetes

Region

Japan


Condition

Condition

hyperlipidemic patients with type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the impact of aggressive lipid control with Rosuvastatin administration on features of carotid intima-media thickness (IMT) and arteriosclerosis of hyperlipidemic patients with type 2 diabetes.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

changes in low-density lipoprotein (LDL) levels after 52 weeks of treatment were analyzed

Key secondary outcomes

mean-IMT, maximal IMT (max-IMT), and max-IMT of the common carotid artery (CCA max-IMT), and ABI (ankle-branchial index), and CAVI(cardio ankle vascular index) after 52 weeks of treatment were analyzed


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rosuvastatin drug was administered at a dose of 5 mg for 52 weeks to hyperlipidemic patients with type 2 diabetes with max-IMT over 1.1 mm despite prior oral administration of a low-intensity statin for at least 3 months.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

hyperlipidemic patients with type 2 diabetes who had been treated with a low oral dose of a strong or a mild statin (Pitavastatin 1mg, Atorvastatin 5mg, Pravastatin, Simvastatin, Fluvastatin) for 3 months or more were enrolled (with max-IMT over 1.1 mm )

Key exclusion criteria

(1)Receiving fibrates
(2)Hemodialysis
(3)Familial hypercholesterolemia
(4)Onset a cerebrovascular accident during the preceding period of less than 3 months
(5)Severe liver dysfunction (AST over 100IU/L, ALT over 100IU/L, Total bilirubin over 2.5mg/dl)
(6)Severe renal dysfunction (serum creatinine over 2.0mg/dl, Ccr 30mL/min
(7)Creatine Kinase over 500IU/L
(8)Receiving cyclosporine
(9)Pregnant or possibly pregnant
(10)Hypothyroidism or hereditary myopathy, a family history of these diseases, and a past history of drug-induced myopathy
(11)Drug abuse or alcoholism
(12)Malignancy
(13)Serious complications

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name TAKANORI KUDO

Organization

Hachinohe City Hospital

Division name

Department of Endocrinology and Diabetes

Zip code


Address

Tamukai aza bisyamontaira 1, hachinohe, Aomori

TEL

0178-72-5111

Email

t-ku-do@pb3.so-net.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name TAKANORI KUDO

Organization

Hachinohe City Hospital

Division name

Department of Endocrinology and Diabetes

Zip code


Address

Tamukai aza bisyamontaira 1, hachinohe, Aomori

TEL

0178-72-5111

Homepage URL


Email

t-ku-do@pb3.so-net.ne.jp


Sponsor or person

Institute

Hachinohe City Hospital Department of Endocrinology and Diabetes

Institute

Department

Personal name



Funding Source

Organization

Hachinohe City Hospital Department of Endocrinology and Diabetes

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 04 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 05 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 06 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 04 Month 20 Day

Last modified on

2018 Year 09 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019956


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name